{"type":"trials","record":{"id":402,"source_id":"clinicaltrials-gov","external_id":"NCT07144527","title":"Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","brief_summary":"This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Scott Silveira","enrollment":40,"countries":["United States"],"start_date":"2026-02-21","completion_date":"2027-01-01","last_update_date":"2026-02-20","source_url":"https://clinicaltrials.gov/study/NCT07144527","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:45:04.314999+00:00","last_seen_at":"2026-09-25T07:05:20.248+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years to 80 Years","comparator":null,"organization":"Concordia University Chicago","interventions":["NMN, betaine, low-dose hydrogen peroxide (EGA)","Nicotinamide Mononucleotide (NMN)","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM). — Measured at the beginning and end of each 4-week in…","Peak Oxygen Uptake (VO2max) — Measured at the beginning and end of each 4-week intervention period.","Lactate Threshold — Measured at the beginning and end of each 4-week intervention period.","Anaerobic Work Capacity — Measured at the beginning and end of each 4-week intervention period.","Critical Power — Measured at the beginning and end of each 4-week intervention period.","Circulating NAD+ and Related Metabolites — Measured at the beginning and end of each 4-week intervention period."],"design_description":"RANDOMIZED · CROSSOVER · BASIC SCIENCE · QUADRUPLE","source_has_results":false},"controlled_terms":["Aging","Frailty","Exercise Tolerance","Healthy Male and Female Subjects","NMN, betaine, low-dose hydrogen peroxide (EGA)","Nicotinamide Mononucleotide (NMN)","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: nicotinamide mononucleotide.","quality_checked_at":"2026-09-25T07:05:30.295959+00:00","duplicate_cluster_key":"id:nct07144527","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-02-21 to 2027-01-01","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T07:05:20.285Z","intervention":["NMN, betaine, low-dose hydrogen peroxide (EGA)","Nicotinamide Mononucleotide (NMN)","Placebo"],"participants":40,"study_design":"RANDOMIZED · CROSSOVER · BASIC SCIENCE · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM). — Measured at the beginning and end of each 4-week in…","Peak Oxygen Uptake (VO2max) — Measured at the beginning and end of each 4-week intervention period.","Lactate Threshold — Measured at the beginning and end of each 4-week intervention period.","Anaerobic Work Capacity — Measured at the beginning and end of each 4-week intervention period.","Critical Power — Measured at the beginning and end of each 4-week intervention period.","Circulating NAD+ and Related Metabolites — Measured at the beginning and end of each 4-week intervention period."],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"exercise","is_published":true,"match_reasons":["Title contains controlled term: exercise.","Abstract contains controlled term: exercise.","Source terminology contains: exercise.","Title supplies longevity context: older adult.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Exercise","slug":"exercise"}},{"topic_slug":"nad-metabolism","is_published":true,"match_reasons":["Title contains controlled term: nicotinamide mononucleotide.","Abstract contains controlled term: nad+, nicotinamide mononucleotide.","Source terminology contains: nicotinamide mononucleotide, nmn.","Title supplies longevity context: older adult.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"NAD metabolism","slug":"nad-metabolism"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/402","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}